Product Images Losartan Potassium
View Photos of Packaging, Labels & Appearance
- 25 mg,90 Tablets/bottle - 8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 06
- 50 mg 30 Tablets - 8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 07
- 100 mg 30 Tablets - 8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 08
- Chemical Structure - spl image1 structure1
- Figure 1 - spl image2 figure1
- Figure 2 - spl image3 figure2
- Figure 3 - spl image4 figure3
- Figure 4 - spl image5 figure4
Product Label Images
The following 8 images provide visual information about the product associated with Losartan Potassium NDC 67296-2057 by Redpharm Drug, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
25 mg,90 Tablets/bottle - 8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 06
This text appears to be a label or information related to a medication called Losartan Potassium Tablets, USP. It provides details such as the manufacturer (Fong i Pramasescal Co.), recommended storage conditions (controlled room temperature), quantity (90 tablets), and doses (25 mg). There are also references to NDC codes and distributor details. Additionally, the text mentions that the tablets should be kept in the original container and that the box is designed to dispense with ease.*
50 mg 30 Tablets - 8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 07
100 mg 30 Tablets - 8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 08
Chemical Structure - spl image1 structure1
Figure 1 - spl image2 figure1
This text provides a comparison between Atenolol and Losartan Potassium in terms of their effectiveness in reducing the primary endpoint in patients. The study shows an adjusted risk reduction of 13% with a statistically significant p-value of 0.021 over a 66-month period.*
Figure 2 - spl image3 figure2
This text provides information on a medication switch from Atenolol to Losartan Potassium with an adjusted risk reduction of 25% and a p-value of 0.001. It also presents the percentage of patients with fatal/non-fatal stroke at different study months, ranging from 6 to 66.*
Figure 3 - spl image4 figure3
This is a table showing the primary endpoint events within different demographic subgroups in a study comparing Losartan and Atenolol for stroke prevention. The table includes data on event rates, hazard ratios, and subgroup breakdowns based on age, gender, race, history of cardiovascular disease, diabetes, and isolated systolic hypertension. These results are adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy. The sample includes a diverse range of racial backgrounds such as Black, White, Asian, Hispanic, Asiatic, Multi-race, Indian, Native American, and European.*
Figure 4 - spl image5 figure4
This text shows the comparison of patients with an event between those taking Losartan Potassium and Placebo over a 48-month period. The data indicates a risk reduction of 16.1% in patients taking Losartan Potassium compared to Placebo, with a statistical significance of p=0.022.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
